EPROSPECTS OF USING 225AC IN ALPHA-PARTICLE RADIOIMMUNOTHERAPY OF MALIGNANT NEOPLASMS
One of the most promising areas of nuclear medicine is the development of radiopharmaceuticals for cancer treatment. Their clinical effectiveness is largely determined by the ability to deliver radionu- clides directly to the affected organ. In a brief overview based on experimental and theoretical data on the physical and chemical properties of the actinium compounds, the possibility of creating a new gen- eration 225Ac-based radiopharmaceuticals is analyzed. The prospects of using carbon-based actinium complexes as components of targeted therapy agents and the potential role of first principle-based ap- proach in drug design are discussed.